Antony Blanc
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michael Brosnan | M | 69 | 1 Jahre | |
| Klaus Schollmeier | M | 67 | 2 Jahre | |
| Alexander Zehnder | M | 54 | 1 Jahre | |
| Tobias Ohler | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 27 Jahre |
| Debra Stephanie Barker | M | 61 | 2 Jahre | |
| Malte Greune | M | 59 | 3 Jahre | |
| Myriam Mendila | M | 58 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michael Pragnell | M | 77 | 7 Jahre | |
| Mark Moran | M | 64 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| John Ramsay | M | 66 | 16 Jahre | |
| Michael T. Mack | M | 64 | 7 Jahre | |
| Robert Berendes | M | 59 | 12 Jahre | |
| Felix Weber | M | 73 | 13 Jahre | |
| Ralph Heck | M | 67 |
Mckinsey & Co., Inc. (Germany)
| 28 Jahre |
| Florian von der Muelbe | M | 52 | 21 Jahre | |
| John Atkin | M | 70 | 14 Jahre | |
| Gavin Hill | M | 56 | 2 Jahre | |
| Alejandro A. Aruffo | M | 63 | 5 Jahre | |
| Rolf Urs Watter | M | 66 | 12 Jahre | |
| Pierre Landolt | M | 77 | 12 Jahre | |
| Peter M. Thompson | M | 77 | 13 Jahre | |
| Peggy Bertha Bruzelius | F | 74 | 13 Jahre | |
| Jacques Vincent | M | 78 | - | |
| Timothy M. Wright | M | 69 | 3 Jahre | |
| Mariola Fotin-Mleczek | M | 50 | 16 Jahre | |
| Simon Warner | M | - | 6 Jahre | |
| Arno Antlitz | M | 54 |
Mckinsey & Co., Inc. (Germany)
| - |
| Christoph Mäder | M | 64 | 18 Jahre | |
| Andreas Ulf Krinninger | M | 56 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| John Kristin Sirchio | M | 58 | 5 Jahre | |
| Michael Escher | M | - | 5 Jahre | |
| Sabine Bendiek | F | 58 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Ralf Clemens | M | 71 | 8 Jahre | |
| Bernard Bollag | M | 63 | 5 Jahre | |
| Günther Thallinger | M | 52 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Simon Lees | M | - | 3 Jahre | |
| Michael Erich Matthias Hammes | M | 69 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Erik Stefan Leyers | M | 54 |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Philipp Carlsson-Szlezak | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Bettina Orlopp | M | 53 |
Mckinsey & Co., Inc. (Germany)
| - |
| Achim Dünnwald | M | 55 |
Mckinsey & Co., Inc. (Germany)
| 12 Jahre |
| Mrinay Nair | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Cornelius Baur | M | 61 |
Mckinsey & Co., Inc. (Germany)
| 25 Jahre |
| Igor Splawski | M | 56 | 3 Jahre | |
| Bernd Winterhalter | M | 65 | 2 Jahre | |
| Michael Rudolf | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 10 Jahre |
| Michael Peters | M | - |
Mckinsey & Co., Inc. (Germany)
| 11 Jahre |
| Jochen Linck | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 11 Jahre |
| Andreas Wolf | M | - |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Yassin Hankir | M | - |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Michael Ollmann | M | 66 |
Mckinsey & Co., Inc. (Germany)
| 17 Jahre |
| Sopna Sury | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Klaus Edvardsen | M | 62 | 1 Jahre | |
| Marcus Johannes Chromik | M | 52 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Damian Heller | M | 58 | 7 Jahre | |
| Markus Scheuermann | M | 51 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Piotr Doniec | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Jeffrey R. Beard | M | - | 20 Jahre | |
| Dirk W. Kirsten | M | 56 | 4 Jahre | |
| Timm Richter | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Dirk Markus | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Zachary McNealy | M | 50 |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | 3 Jahre |
| Dorothea Wenzel | M | 55 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| André Krause | M | 54 |
Mckinsey & Co., Inc. (Germany)
| 5 Jahre |
| Stephen L. Bandak | M | 74 |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | 4 Jahre |
| Christian Diekmann | M | 58 |
Mckinsey & Co., Inc. (Germany)
| 4 Jahre |
| Gert Purkert | M | 53 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Richard Steiblin | M | 74 | 3 Jahre | |
| Uwe Meya | M | - |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| Stefan Borgas | M | 59 | 8 Jahre | |
| Rupert Gasser | M | - | 7 Jahre | |
| Peter Doyle | M | - | 9 Jahre | |
| Domenico Scala | M | 59 | 4 Jahre | |
| David Lawrence | M | 75 | 8 Jahre | |
| Heinz Imhof | M | - | 5 Jahre | |
| Desmond J. Fitzgerald | M | - |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | - |
| Frank Appel | M | 62 |
Mckinsey & Co., Inc. (Germany)
| 1 Jahre |
| Jürg Witmer | M | 75 | - | |
| Arnoud A. Middel | M | 53 | 3 Jahre | |
| Mark Peacock | M | 63 | 10 Jahre | |
| Stefan Blarer | M | - | 6 Jahre | |
| Florian Kawohl | M | - |
Mckinsey & Co., Inc. (Germany)
| 2 Jahre |
| Christoph Vilanek | M | 56 |
Mckinsey & Co., Inc. (Germany)
| 3 Jahre |
| Stephan Kirschbaum | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Martin Taylor | M | 71 | 13 Jahre | |
| Antoinette P. Aris | F | 65 |
Mckinsey & Co., Inc. (Germany)
| 18 Jahre |
| Franz-Werner Haas | M | 54 | 11 Jahre | |
| Kristian Schleede | M | 66 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Leonhard Birnbaum | M | 57 |
Mckinsey & Co., Inc. (Germany)
| 12 Jahre |
| Benedikt Timmerman | M | 65 | 3 Jahre | |
| Christopher Hoffmann | M | 50 |
Mckinsey & Co., Inc. (Germany)
| 6 Jahre |
| Davor Pisk | M | 66 | 8 Jahre | |
| Stephan Leithner | M | 58 |
Mckinsey & Co., Inc. (Germany)
| 7 Jahre |
| Hans Tanner | M | 72 | 8 Jahre | |
| Thomas Vollmoeller | M | 64 |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
| Michaela Schäfer | M | - |
Mckinsey & Co., Inc. (Germany)
| 9 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Deutschland | 55 | 57,29% |
| Schweiz | 41 | 42,71% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Antony Blanc
- Persönliches Netzwerk
